SK pharmteco
Khan Umaer is an experienced research scientist with a focus on biotechnology and downstream process development. Currently serving as a Research Scientist-II at SK pharmteco, Khan specializes in the development of AAV and LVV purification and analytical strategies, as well as designing and executing DoE studies for chromatographic purification optimization. Previous roles include Research Scientist-I at the Center for Breakthrough Medicines and downstream process development at The Janssen Pharmaceutical Companies of Johnson & Johnson, where Khan contributed to COVID-19 vaccine development. Khan's early career involved postdoctoral research at the University at Buffalo, investigating the role of Rab proteins in secretory and endocytic trafficking in trypanosomes. Khan holds a PhD in Microbiology and Immunology from the University at Buffalo, along with MS and BS degrees in Biochemistry and Molecular Biology from the University of Dhaka.
This person is not in any teams
This person is not in any offices
SK pharmteco
Headquartered in Rancho Cordova, California, SK pharmteco is a global contract development and manufacturing organization specializing in the production of active pharmaceutical ingredients (APIs), advanced intermediates, and cell and gene therapy for the pharmaceutical industry. Built on 80 years of experience, our global operations have the capability and capacity to support client needs from development through commercial production. SK pharmteco is owned by SK Inc., the strategic investment arm of South Korea’s SK Group.